ea0081p531 | Adrenal and Cardiovascular Endocrinology | ECE2022
Alessi Ylenia
, Luisa Torre Maria
, Giovinazzo Salvatore
, Giuffrida Giuseppe
, Giandalia Annalisa
, Casablanca Rosalinda
, Flavio Angileri Filippo
, Ragonese Marta
, Ferrau Francesco
, Cannavo Salvatore
Pasireotide is the first pituitary-directed approved therapy for Cushings disease (CD), effective in reducing UFC >50% in about half of patients, and with a good tolerability profile but associated with a relatively high incidence of hyperglicemia. The aim of this study was to evaluate efficacy and safety of long-term treatment with pasireotide (PAS) in patients with CD. Methods: We retrospectively evaluated 17 consecutive patients (11 females) with CD treated with P...